000			01463 a2200349 4500
005			20250515164602.0
264		0	_c20090803
008			200908s 0 0 eng d
022			_a1365-2141
024	7		_a10.1111/j.1365-2141.2009.07657.x _2doi
040			_aNLM _beng _cNLM
100	1		_aTeachey, David T
245	0	0	_aMammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. _h[electronic resource]
260			_bBritish journal of haematology _cJun 2009
300			_a569-80 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aAutoimmune Diseases _xdrug therapy
650	0	4	_aHematologic Neoplasms _xdrug therapy
650	0	4	_aHumans
650	0	4	_aLeukemia _xdrug therapy
650	0	4	_aLymphoproliferative Disorders _xdrug therapy
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProtein Kinases _xmetabolism
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSirolimus _xtherapeutic use
650	0	4	_aTOR Serine-Threonine Kinases
700	1		_aGrupp, Stephan A
700	1		_aBrown, Valerie I
773	0		_tBritish journal of haematology _gvol. 145 _gno. 5 _gp. 569-80
856	4	0	_uhttps://doi.org/10.1111/j.1365-2141.2009.07657.x _zAvailable from publisher's website
999			_c18779679 _d18779679